Annual Current Liabilities
$77.97 M
+$18.27 M+30.60%
December 31, 2023
Summary
- As of February 7, 2025, PHAR annual total current liabilities is $77.97 million, with the most recent change of +$18.27 million (+30.60%) on December 31, 2023.
- During the last 3 years, PHAR annual current liabilities has risen by +$1.12 million (+1.46%).
- PHAR annual current liabilities is now -31.76% below its all-time high of $114.25 million, reached on December 31, 2019.
Performance
PHAR Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$79.84 M
-$98.00 K-0.12%
September 30, 2024
Summary
- As of February 7, 2025, PHAR quarterly total current liabilities is $79.84 million, with the most recent change of -$98.00 thousand (-0.12%) on September 30, 2024.
- Over the past year, PHAR quarterly current liabilities has dropped by -$127.45 million (-61.48%).
- PHAR quarterly current liabilities is now -61.48% below its all-time high of $207.28 million, reached on March 31, 2024.
Performance
PHAR Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
PHAR Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +30.6% | -61.5% |
| 3 y3 years | +1.5% | +70.7% |
| 5 y5 years | -17.5% | -19.0% |
PHAR Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +66.7% | -61.5% | +76.8% |
| 5 y | 5-year | -31.8% | +66.7% | -61.5% | +86.3% |
| alltime | all time | -31.8% | +1053.3% | -61.5% | +725.1% |
Pharming Group NV Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $79.84 M(-0.1%) |
| Jun 2024 | - | $79.94 M(-61.4%) |
| Mar 2024 | - | $207.28 M(+165.9%) |
| Dec 2023 | $77.97 M(+30.6%) | $77.97 M(+14.6%) |
| Sep 2023 | - | $68.06 M(+4.8%) |
| Jun 2023 | - | $64.95 M(+10.1%) |
| Mar 2023 | - | $59.00 M(-1.2%) |
| Dec 2022 | $59.70 M(+27.6%) | $59.70 M(+27.8%) |
| Sep 2022 | - | $46.69 M(-5.1%) |
| Jun 2022 | - | $49.19 M(+9.0%) |
| Mar 2022 | - | $45.15 M(-3.5%) |
| Dec 2021 | $46.77 M(-39.1%) | $46.77 M(+0.1%) |
| Sep 2021 | - | $46.72 M(-2.3%) |
| Jun 2021 | - | $47.84 M(-35.1%) |
| Mar 2021 | - | $73.71 M(-4.1%) |
| Dec 2020 | $76.85 M(-32.7%) | $76.85 M(+79.3%) |
| Sep 2020 | - | $42.86 M(-13.2%) |
| Jun 2020 | - | $49.36 M(+0.8%) |
| Mar 2020 | - | $48.97 M(-57.1%) |
| Dec 2019 | $114.25 M(+20.9%) | $114.25 M(+15.9%) |
| Sep 2019 | - | $98.58 M(+31.4%) |
| Jun 2019 | - | $75.01 M(+7.3%) |
| Mar 2019 | - | $69.93 M(-26.0%) |
| Dec 2018 | $94.49 M(+29.7%) | $94.49 M(-5.8%) |
| Sep 2018 | - | $100.26 M(+34.7%) |
| Jun 2018 | - | $74.43 M(+2.1%) |
| Mar 2018 | - | $72.89 M(+0.0%) |
| Dec 2017 | $72.87 M(+34.9%) | $72.87 M(+10.6%) |
| Sep 2017 | - | $65.91 M(+67.2%) |
| Jun 2017 | - | $39.42 M(-40.1%) |
| Mar 2017 | - | $65.82 M(+21.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $54.03 M(+266.8%) | $54.03 M(+163.4%) |
| Sep 2016 | - | $20.52 M(-0.1%) |
| Jun 2016 | - | $20.54 M(+10.7%) |
| Mar 2016 | - | $18.55 M(+25.9%) |
| Dec 2015 | $14.73 M(-18.5%) | $14.73 M(-5.9%) |
| Sep 2015 | - | $15.65 M(+12.0%) |
| Jun 2015 | - | $13.98 M(-8.4%) |
| Mar 2015 | - | $15.26 M(-15.7%) |
| Dec 2014 | $18.09 M(+1.3%) | $18.09 M(+7.9%) |
| Sep 2014 | - | $16.76 M(-25.4%) |
| Jun 2014 | - | $22.46 M(+23.3%) |
| Mar 2014 | - | $18.22 M(+2.1%) |
| Dec 2013 | $17.85 M(+50.5%) | $17.85 M(+24.8%) |
| Sep 2013 | - | $14.30 M(-26.1%) |
| Jun 2013 | - | $19.35 M(-26.4%) |
| Mar 2013 | - | $26.28 M(+121.6%) |
| Dec 2012 | $11.86 M(+12.5%) | $11.86 M(-9.8%) |
| Sep 2012 | - | $13.15 M(-30.6%) |
| Mar 2012 | - | $18.93 M(+79.5%) |
| Dec 2011 | $10.54 M(-18.1%) | $10.54 M(+9.0%) |
| Sep 2011 | - | $9.68 M(+0.0%) |
| Jun 2011 | - | $9.68 M(-9.7%) |
| Mar 2011 | - | $10.72 M(-16.8%) |
| Dec 2010 | $12.88 M(-75.2%) | $12.88 M(-49.4%) |
| Sep 2010 | - | $25.45 M(-59.4%) |
| Jun 2010 | - | $62.73 M(-5.0%) |
| Mar 2010 | - | $66.01 M(+27.0%) |
| Dec 2009 | $51.97 M(+42.5%) | $51.97 M |
| Dec 2008 | $36.46 M(+6.2%) | - |
| Dec 2007 | $34.33 M(+183.0%) | - |
| Dec 2006 | $12.13 M(+79.5%) | - |
| Dec 2005 | $6.76 M | - |
FAQ
- What is Pharming Group NV annual total current liabilities?
- What is the all time high annual current liabilities for Pharming Group NV?
- What is Pharming Group NV annual current liabilities year-on-year change?
- What is Pharming Group NV quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Pharming Group NV?
- What is Pharming Group NV quarterly current liabilities year-on-year change?
What is Pharming Group NV annual total current liabilities?
The current annual current liabilities of PHAR is $77.97 M
What is the all time high annual current liabilities for Pharming Group NV?
Pharming Group NV all-time high annual total current liabilities is $114.25 M
What is Pharming Group NV annual current liabilities year-on-year change?
Over the past year, PHAR annual total current liabilities has changed by +$18.27 M (+30.60%)
What is Pharming Group NV quarterly total current liabilities?
The current quarterly current liabilities of PHAR is $79.84 M
What is the all time high quarterly current liabilities for Pharming Group NV?
Pharming Group NV all-time high quarterly total current liabilities is $207.28 M
What is Pharming Group NV quarterly current liabilities year-on-year change?
Over the past year, PHAR quarterly total current liabilities has changed by -$127.45 M (-61.48%)